Preparation method of CHO-K1 monoclonal cell strain with GS dialleles knocked out

By directly knocking out GS genes using RNP complex composed of Cas9 and sgRNA in CHO-K1 cells, the problem of resistance genes and transfection difficulty introduced by plasmid vectors in the prior art was solved, and efficient and safe double-elements were achieved Effects of loci knockout and high expression of recombinant proteins.

CN118879784APending Publication Date: 2024-11-01ZHEJIANG LONGI BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410966443.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

When performing GS gene knockout in CHO cells, it is necessary to construct a plasmid vector, resulting in difficulty in introducing and transfection of resistance genes, high cost and possible off-target effects, affecting cell safety and efficiency.

Method used

The RNP complex composed of Cas9 and sgRNA was used to directly transfect CHO-K1 cells to avoid the use of plasmid vectors, ensure efficient knockdown of GS genes, and to achieve biallelic knockdown by designing multiple sgRNAs to target different sites.

Benefits of technology

Efficient and safe GS biallele knockdown is achieved, avoiding the difficulty of introducing and transfecting resistance genes, shortening the knockout cycle, and improving the stability of cell lines and the efficiency of recombinant protein expression.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118879784A_ABST
    Figure CN118879784A_ABST
Patent Text Reader

Abstract

The invention relates to the field of bioengineering, and discloses a preparation method of a CHO-K1 monoclonal cell strain with GS dialleles knocked out. According to the invention, Cas9 and sgRNA are delivered into CHO cells, and no carrier containing resistance genes and screening genes is introduced into the cells, so that damage to the CHO cells can be avoided. The RNP complex can be degraded without the possibility of being integrated into the host genome. And finally, the RNP complex does not need to be translated in the cell to obtain the Cas9 protein, and the RNP complex can begin to act once being delivered into the cell, so that the relatively high cutting efficiency can be obtained. In addition, the construction of expensive and time-consuming plasmid vectors can be avoided, and the GS knockout period can be shortened. In conclusion, the method is more suitable for the CHO cells, and particularly the CHO cells after the GS genes are knocked out are used for biological medicine and raw material production, so that the method is safer and more practical.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of bioengineering, and in particular to a method for preparing a GS double allele knockout CHO-K1 monoclonal cell line. Background Art

[0002] Chinese hamster ovary cells (CHO cells) are currently the most widely used mammalian expression system in the field of biopharmaceuticals. CHO cells were established in 1957 by Theodore T. Puck of the University of Colorado, USA, who isolated them from the ovary of an adult female Chinese hamster. CHO cells are a continuous cell line that can be propagated for more than a hundred generations and are immortal (immortal). They are currently the most widely recognized cell line in bioengineering. CHO cells have many significant characteristics, such as the ability to produce post-translationally modified proteins similar to those of humans and the ability to undergo complex glycosylation; CHO cells are non-secreting cells that rarely secrete CHO endogenous proteins themselves, and CHO cells are also easy to transfect, making them a common choice for transient and stable expression in research; CHO cells have good genomic background characteristics and have a relatively fast growth rate and high protein expression yield in suspension culture; in addition, CHO cells proliferate rapidly, making them very suitable for large-scale culture, and have the advantages of high stability and easy operation. CHO cell large-scale culture technology and its bioreactor engineering can be widely used in the research, development and industrial production of biotechnology products such as antibodies, recombinant protein drugs, and viral vaccines.

[0003] After more than 60 years of research history, CHO cells have derived a variety of cell lines with different properties from the original cell line. CHO-K1 cells are one of them and are widely used. CHO-K1 cells were born in 1957 and are subclones of early CHO cells. They have not been modified and are wild-type cells. However, mutation analysis in 1968 showed that CHO-K1 cells lack genes for glycine biosynthesis and have less DNA than the original CHO cells. In 1970, the Puck laboratory subcloned the original CHO cell line and deposited it in the ATCC (CCL-61) series. Subsequently, in 1985, the ATCC CHO-K1 subclone was isolated and stored in ECACC (85051005), at which time the cell line began to be used for pharmaceuticals or recombinant protein expression. The culture method of the CHO-K1 cell line adopts adherent culture, and serum needs to be added to the culture medium to ensure good cell growth. There are two screening systems in CHO cells: dihydrofolate reductase (DHFR) and glutamine synthetase (GS). The protein screening systems mainly used in CHO-K1 cell lines are GS (glutamine synthetase) and antibiotic screening systems, which have also improved screening efficiency. Currently, many therapeutic proteins that have been launched on the market are mostly developed and produced based on CHO-K1 cells. Lonza Biotech has transformed and trained ECACC CHO-K1 for many years to establish CHO K1SV (Lonza, 2002) cell lines to adapt them to serum-free medium suspension culture, which is widely used in GS expression platforms. Merck obtained CHO-K1 cell lines through ECACC in 2006, and established CHOZN CHO K1 (Merck, 2006) cell lines through suspension domestication. This cell line can grow in chemically defined medium, reducing the culture cost. The Horizon Discovery CHO engineered cell line is derived from ECACC (European Cell Bank) CHO-K1 cells. Using Horizon Discovery's recombinant adenovirus (rAAV) technology, the sixth exon (an essential element for enzyme catalytic activity) of the GS gene (glutamine synthetase) is knocked out through homologous recombination to obtain a CHO-K1 cell line without the glutamine synthetase gene. The cell line is further domesticated into suspension cells and adapted to the existing commercial chemical-defined animal-free culture medium, thereby obtaining a CHO cell line that stably produces protein drugs / antibody drugs - HD-BioP3.

[0004] The GS screening system is a newly developed and more efficient amplification expression screening system. The culture and growth process of CHO cells requires glutamine (L-glutamine). GS converts glutamate and ammonia into glutamine, and animal cells obtain glutamine through this enzymatic reaction. In the GS screening system, the recombinant protein expression vector carrying exogenous GS is first transfected into CHO cells. CHO cells obtain exogenous GS and express it, and use glutamate and ammonia in the culture medium to synthesize glutamine for cell culture and growth. Therefore, the culture medium used before and during transfection should be a complete culture medium with glutamine added. When the plasmid is transfected and integrated into CHO cells, the culture medium without glutamine is used so that only cells transfected with the exogenous GS gene and the target protein gene can grow, achieving the purpose of screening and obtaining recombinant expression cell lines. During the culture process, if the GS inhibitor methionine sulfhydrylamine (MSX) is added, the expression of the GS gene can be inhibited. Only when the GS gene is amplified to a large number of copies can it survive. Therefore, under the drug pressure of MSX, the anti-MSX cell line obtained is a high-level expression of the GS gene, and also a high-level expression of the target gene, thereby obtaining a recombinant expression screening strain with higher expression. On this basis, CHO-K1 (GS- / -) cells with GS gene knocked out completely lack endogenously expressed GS. When cultured without glutamine and screened with MSX, a recombinant expression screening strain with higher expression than cells with endogenous GS can be obtained. Therefore, GS knocked out defective CHO-K1 cells are widely used in the fields of biopharmaceuticals and biological raw material production.

[0005] In CHO cells, researchers have used different gene editing technologies to knock out the GS gene. CRISPR / Cas9 is currently the most widely used gene editing technology with the highest knockout efficiency and the best operability. In many species and tissues, the CRISPR / Cas9 gene editing method has achieved successful cases, and its clinical application has been carried out worldwide. When performing CRISPR / Cas9 gene editing, the introduction of Cas9 protein and guide RNA (sgRNA) is the most critical step. Depending on the host being edited, Cas9 and sgRNA can be introduced in a variety of ways, such as electrofection, chemical transfection, viral infection and physical injection. When performing gene editing in CHO cells, the method of introducing Cas9 and sgRNA is mainly to construct a plasmid vector to carry Cas9 and sgRNA, and then electrofect the plasmid vector into the cell. The advantage of this delivery method is that Cas9 and sgRNA can be expressed in cells for a long time and efficiently, so their action time is continuous and long. At the same time, this delivery method also has its disadvantages: 1) Because plasmid vectors can exist in cells for a long time and express Cas9 and sgRNA, possible off-target effects will continue to amplify, increasing the unsafe factor; 2) Because plasmid vectors carry Cas9 and sgRNA, the difficulty of electrotransfection is increased and the transfection efficiency is reduced; 3) The preparation of Cas9 and sgRNA carrier vectors is time-consuming, labor-intensive and expensive; 4) When introducing the vector, resistance genes or screening genes will inevitably be introduced, causing certain damage to CHO cells and bringing inconvenience to the subsequent production process. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides a method for preparing a GS biallelic knockout CHO-K1 monoclonal cell line. The method of the present invention can efficiently knock out GS biallelic genes in CHO-K1 cells. The method of the present invention can avoid the use of plasmid vectors, does not introduce any resistance genes, does not leave any Cas9 genes, and has high safety. In addition, the method of the present invention can avoid the construction of expensive and time-consuming plasmid vectors, and can shorten the cycle of GS knockout.

[0007] The specific technical scheme of the present invention is: a method for preparing a CHO-K1 monoclonal cell line with GS biallelic gene knockout, comprising the following steps: 1) Analyze the GS gene on chromosome 5 and chromosome 1 of CHO-K1 cells, develop a knockout plan and design the Cas9-guided sgRNA sequence (i.e., crRNA) that recognizes the GS gene.

[0008] 2) Connect the tracrRNA sequence to the sgRNA sequence and synthesize PCR reaction primers.

[0009] 3) Perform PCR amplification using PCR reaction primers, recover and purify to obtain the sgRNA in vitro transcription template.

[0010] 4) Using the sgRNA in vitro transcription template, in vitro transcription under the action of RNA polymerase obtains a complete sgRNA containing the sgRNA sequence and the tracrRNA sequence.

[0011] 5) The sgRNA is combined with the Cas9 protein to form an RNP complex, which is then transfected into CHO-K1 cells.

[0012] 6) The transfected CHO-K1 cells were subjected to monoclonal culture to obtain a CHO-K1 monoclonal cell line with GS biallelic gene knockout.

[0013] As described in the background technology section, when performing gene editing in CHO cells, the method of introducing Cas9 and sgRNA is mainly to construct a plasmid vector to carry Cas9 and sgRNA, and then electro-transfect the plasmid vector into the cell. This delivery method has the following disadvantages: the plasmid vector can exist in the cell for a long time and continuously express Cas9 and sgRNA; the plasmid vector is difficult to transfect because it carries Cas9 and sgRNA; the preparation of the carrier vector of Cas9 and sgRNA is time-consuming and costly; the plasmid vector will introduce resistance genes and screening genes that are not needed later.

[0014] The above method of the present invention is used to deliver Cas9 and sgRNA into CHO cells. This method does not introduce any vectors containing resistance genes and screening genes into the cells, which can avoid damage to CHO cells. The RNP complex will be degraded and there is no possibility of being integrated into the host genome. Finally, because the RNP complex does not need to undergo a translation process in the cell to obtain the Cas9 protein, it can start to work once it is delivered into the cell, so a higher cutting efficiency can be obtained. In addition, the method of the present invention can avoid the construction of expensive and time-consuming plasmid vectors, and can shorten the cycle of GS knockout. In summary, the method of the present invention is more suitable for CHO cells, especially CHO cells after knocking out the GS gene are used in the production of biopharmaceuticals and raw materials, which will be safer and more practical.

[0015] Preferably, in 1), two sgRNAs are designed for each GS gene on each chromosome; wherein: For chromosome 5, there are sgRNA sequences targeting intron 1 and sgRNA sequences targeting exon 7; Targeting chromosome 1 are 5' end targeting sgRNA sequence and 3' end targeting sgRNA sequence.

[0016] Preferably, in 1), the sgRNA sequence targeting intron 1 is shown as SEQ ID NO.17; the sgRNA sequence targeting exon 7 is shown as SEQ ID NO.18; the 5' end targeting sgRNA sequence is shown as SEQ ID NO.19; and the 3' end targeting sgRNA sequence is shown as SEQ ID NO.20.

[0017] Preferably, in 2), the tracrRNA sequence is as shown in SEQ ID NO.21.

[0018] Preferably, in 2), the PCR reaction primers include: for chromosome 5: the forward primer sequence of the sgRNA targeting intron 1 is shown in SEQ ID NO.22; the forward primer sequence of the sgRNA targeting exon 7 is shown in SEQ ID NO.23; for chromosome 1: the forward primer sequence of the 5' end targeting sgRNA is shown in SEQ ID NO.24; the forward primer sequence of the 3' end targeting sgRNA is shown in SEQ ID NO.25.

[0019] Preferably, in 5), the transfection method is electrofection or liposome transfection.

[0020] Preferably, in 5), the source of the CHO-K1 cells is ATCC: CCL-61.

[0021] Preferably, in 6), the monoclonal culture method is: the transfected CHO-K1 cells are statically cultured, cells with a relatively round shape and medium size are picked up under a microscope using a mouth pipette, one cell is placed in a well, monoclonal plating is performed, and the monoclonal cell wells are checked at two time points after 2 hours and within 24 hours to determine the monoclonal cell wells and exclude the polyclonal cell wells.

[0022] Preferably, in 6), when the confluence rate of monoclonal cells is 55-65%, a portion of cells are taken for DNA extraction, PCR detection and Sanger sequencing verification to obtain a CHO-K1 monoclonal cell line with GS biallelic knockout.

[0023] Preferably, the preparation method further comprises: 7) The CHO-K1 monoclonal cell line with GS double allele knockout was expanded and cryopreserved.

[0024] 8) The GS biallelic knockout CHO-K1 monoclonal cell line obtained in 7) was verified for GS RNA level, protein level and functional defect, and a high-expressing GS biallelic knockout CHO-K1 monoclonal cell line was obtained after screening.

[0025] After obtaining the GS double allele knockout CHO-K1 monoclonal cell strain, the present invention further performs subclone screening to obtain a high-expression monoclonal cell strain. When applied to recombinant protein expression, a high-expression positive clone strain can be obtained in a short period of time without adding glutamine, and the content of the expressed recombinant protein is significantly improved.

[0026] Preferably, 8) specifically includes: A) The GS biallelic knockout CHO-K1 monoclonal cell line was subcloned and plated by mouth pipette selection; B) Expand the culture of the subclone cells that first grow to 70-80% confluence and have uniform cell size and freeze them for seed preservation; C) transfecting the constructed recombinant protein expression vector into the subclone cell line obtained in B); D) The transfected subcloned cell lines were placed in a medium containing glutamine to recover for 48 hours; E) After 48 hours, the subcloned cell lines were placed in a medium without glutamine for screening; F) Continuously monitor the density and viability of subcloned cell lines; G) After the cell viability reaches more than 90%, the growth rate is normal and can be stable for 3 generations, monoclonal plating is performed by mouth pipette selection method; H) When the growth confluence rate of the monoclonal cell line in G) reaches 45-55%, ELISA reaction screening is performed to select the monoclonal cell line with high expression level; I) expanding the culture of the monoclonal clone obtained in H) and performing Fed-Batch induced expression; J) Monitor the expression level of the cell lines in I), analyze the time required for each monoclonal cell line from E) to G), and analyze the expression level of the recombinant protein to select the optimal subclone cell line.

[0027] Compared with the prior art, the beneficial effects of the present invention are: (1) The method of the present invention is used to deliver Cas9 and sgRNA into CHO cells. This method does not introduce any resistance genes and screening genes into the cells, which can avoid damage to CHO cells. The introduced RNP complex will be degraded and there is no possibility of integration into the host genome. In addition, the RNP complex does not need to undergo a translation process in the cell to obtain the Cas9 protein. Once it is delivered into the cell, it can start to work, so the cutting efficiency is higher.

[0028] (2) The method of the present invention can avoid the construction of expensive and time-consuming plasmid vectors and shorten the GS knockout cycle.

[0029] (3) After obtaining the GS double allele knockout CHO-K1 monoclonal cell line, the present invention further obtains a high-expressing monoclonal cell line through subclone screening. When applied to recombinant protein expression, a high-expressing positive clone can be obtained in a short period of time without adding glutamine, and the content of the expressed recombinant protein is significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 Construction of a strategy map for the knockout of GS genes.

[0031] Figure 2 It is the guide RNA for GS gene targeted knockout obtained by in vitro transcription.

[0032] Figure 3 This is a DNA agarose gel electrophoresis verification diagram of GS gene knockout.

[0033] Figure 4 This is the Sanger sequencing verification diagram of GS gene knockout.

[0034] Figure 5 The changes in GS RNA levels in GS gene knockout cells.

[0035] Figure 6 Verification of GS functional deficiency in GS gene knockout cells.

[0036] Figure 7 This is the recombinant expression cycle of the GS gene knockout monoclonal cell line.

[0037] Figure 8 is the expression level of GS gene knockout monoclonal cell line. DETAILED DESCRIPTION

[0038] In order to illustrate the technical means and effects of the present invention, the present invention is further described in detail below with reference to examples and drawings. However, the embodiments of the present invention include but are not limited to these.

[0039] Overall embodiment A method for preparing a GS biallelic gene knockout CHO-K1 monoclonal cell line comprises the following steps: 1) Analyze the GS gene on chromosome 5 and chromosome 1 of CHO-K1 cells, develop a knockout plan and design the Cas9-guided sgRNA sequence (i.e., crRNA) that recognizes the GS gene.

[0040] In some embodiments, two sgRNAs are designed for the GS gene on each chromosome; wherein: for chromosome 5, there are sgRNA sequences targeting intron 1 and sgRNA sequences targeting exon 7; for chromosome 1, there are sgRNA sequences targeting the 5' end and sgRNA sequences targeting the 3' end. Further preferably, the sgRNA sequence targeting intron 1 is shown in SEQ ID NO.17; the sgRNA sequence targeting exon 7 is shown in SEQ ID NO.18; the 5' end targeting sgRNA sequence is shown in SEQ ID NO.19; and the 3' end targeting sgRNA sequence is shown in SEQ ID NO.20.

[0041] 2) Connect the tracrRNA sequence to the sgRNA sequence and synthesize the PCR reaction primers.

[0042] In some embodiments, the tracrRNA sequence is as shown in SEQ ID NO. 21. The PCR reaction primers include: for chromosome 5: the forward primer sequence of the sgRNA targeting intron 1 is shown in SEQ ID NO. 22; the forward primer sequence of the sgRNA targeting exon 7 is shown in SEQ ID NO. 23; for chromosome 1: the forward primer sequence of the 5' end targeting sgRNA is shown in SEQ ID NO. 24; the forward primer sequence of the 3' end targeting sgRNA is shown in SEQ ID NO. 25.

[0043] 3) Perform PCR amplification using PCR reaction primers, recover and purify to obtain a large amount of sgRNA in vitro transcription templates.

[0044] In some embodiments, the recovery concentration of the sgRNA in vitro transcribed template is 0.5-1.5 μg / μl, and its purification method includes but is not limited to gel recovery and phenol chloroform extraction.

[0045] 4) Using the sgRNA in vitro transcription template, in vitro transcription under the action of RNA polymerase obtains an sgRNA containing the sgRNA sequence and the tracrRNA sequence.

[0046] In some embodiments, the RNA polymerase is T7 RNA polymerase, T3 RNA polymerase or SP6 RNA polymerase.

[0047] 5) The sgRNA is combined with the Cas9 protein to form an RNP complex, which is then transfected into CHO-K1 cells.

[0048] In some embodiments, the transfection method is electrofection or liposome transfection. The source of the CHO-K1 cells is ATCC: CCL-61.

[0049] 6) The transfected CHO-K1 cells were subjected to monoclonal culture to obtain a CHO-K1 monoclonal cell line with GS biallelic gene knockout.

[0050] In some embodiments, the monoclonal culture method is: statically culture the transfected CHO-K1 cells, pick up round, medium-sized cells under a microscope using a mouth pipette, place one cell in each well, perform monoclonal plating, and check at two time points, 2 hours later and within 24 hours, to determine the monoclonal cell wells and exclude non-monoclonal cell wells.

[0051] In some more specific embodiments, the static culture medium is OPM-Altair CHO medium.

[0052] In some more specific embodiments, the monoclonal plating methods include but are not limited to mouth pipette selection, limiting dilution method and using Andawang VIPS PRO plating instrument.

[0053] In some more specific embodiments, when the confluence rate of monoclonal cells is 55-65%, a portion of the cells are taken for DNA extraction, PCR detection and Sanger sequencing verification to obtain a CHO-K1 monoclonal cell line with GS biallelic gene knockout.

[0054] In some more specific embodiments, the method of DNA extraction includes but is not limited to alkaline lysis and phenol-chloroform extraction.

[0055] 7) The CHO-K1 monoclonal cell line with GS double allele knockout was expanded and cryopreserved.

[0056] In some embodiments, the expanded culture is subcultured for more than 3 generations.

[0057] 8) The GS biallelic knockout CHO-K1 monoclonal cell line obtained in 7) was subjected to GS RNA level, protein level and functional defect verification (including fluorescence quantitative PCR, Western Blot and cell growth curve observation, etc.), and after screening, a high-expression GS biallelic knockout CHO-K1 monoclonal cell line was obtained.

[0058] In some embodiments, 8) specifically includes: A) A CHO-K1 monoclonal cell line with biallelic knockout of GS was subcloned and plated by mouth pipette selection.

[0059] In some more specific embodiments, in A), the plating method includes but is not limited to the mouth pipette selection method, the limiting dilution method and the Andawang VIPS PRO plating instrument.

[0060] B) The subclone cells that first grow to 70-80% confluence and have uniform cell size are expanded and cryopreserved.

[0061] C) Transfecting the constructed recombinant protein expression vector into the subclone cell line obtained in B).

[0062] In some more specific embodiments, the transfection method includes but is not limited to electro-transfection. The recombinant protein expression vector is a vector that has been constructed in advance and verified to be able to express normally.

[0063] D) The transfected subcloned cell lines were placed in medium containing glutamine to recover for 48 hours.

[0064] In some more specific embodiments, the recovery culture method is static culture in a T25 flask, and the glutamine concentration is 3-5 mM.

[0065] E) The recovered subcloned cell lines were placed in a medium without glutamine for screening.

[0066] F) Continuously monitor the density and viability of subcloned cell lines.

[0067] G) When the cell viability reaches above 90%, the growth rate is normal and can be stable for 3 generations, single clones are plated by mouth pipette selection method.

[0068] H) When the growth confluence rate of the monoclonal cell line in G) reaches 45-55%, ELISA reaction screening is performed to select the monoclonal cell line with high expression level.

[0069] I) The monoclonal clone obtained in H) is expanded and cultured, and Fed-Batch induced expression is performed.

[0070] In some more specific embodiments, in I), the induced expression time is 12-16 days.

[0071] J) Monitor the expression level of the cell lines in I), analyze the time required for each monoclonal cell line from E) to G), and analyze the expression level of the recombinant protein to select the optimal subclone cell line. Specific embodiments Example 1: GS gene knockout The GS gene was found on chromosome 5 and consists of 7 exons. The CDS region starts from the second exon. Exon 6 was found to be an important and indispensable component for the function of the GS gene. A section of base sequence on it is where the action site is located. Its sequence is shown in SEQ ID NO.10 (the exon 6 sequence is marked with an underline, and the action site sequence is marked with a double underline). On chromosome 1, there is a pseudogene of the GS gene. This pseudogene consists of one exon. The sequence on this exon is highly similar to the CDS sequence of the GS gene on chromosome 5, including the action site sequence on exon 6. Its sequence is shown in SEQ ID NO.15 (the exon 6 sequence is marked with an underline, and the action site sequence is marked with a double underline). Based on this, the knockout strategy of the GS gene is as follows: Figure 1 As shown, for the GS gene on CHO-K1 chromosome 5, two sgRNAs were designed to target intron 1 and exon 7 respectively, and the sequence between the two was deleted; for the GS gene on CHO-K1 chromosome 1, two sgRNAs, 5' and 3', were designed to target and knock out its entire exon.

[0073] SEQ ID NO.1: Intron 1 of GS gene on chromosome 5

[0074] SEQ ID NO.2: Exon 2 of GS gene on chromosome 5

[0075] SEQ ID NO.3: Intron 2 of GS gene on chromosome 5

[0076] SEQ ID NO.4: Exon 3 of GS gene on chromosome 5

[0077] SEQ ID NO.5: Intron 3 of GS gene on chromosome 5

[0078] SEQ ID NO.6: Exon 4 of GS gene on chromosome 5

[0079] SEQ ID NO.7: Intron 4 of GS gene on chromosome 5

[0080] SEQ ID NO.8: Exon 5 of GS gene on chromosome 5

[0081] SEQ ID NO.9: Intron 5 of GS gene on chromosome 5

[0082] SEQ ID NO.10: Exon 6 of GS gene on chromosome 5

[0083] SEQ ID NO.11: Intron 6 of GS gene on chromosome 5

[0084] SEQ ID NO.12: Exon 7 of GS gene on chromosome 5

[0085] SEQ ID NO.13: 3'UTR of GS gene on chromosome 5

[0086] SEQ ID NO.14: 5'UTR of GS gene on chromosome 1

[0087] SEQ ID NO.15: Exon of GS gene on chromosome 1

[0088] SEQ ID NO.16: 3'UTR of GS gene on chromosome 1

[0089] (1) Comprehensively analyze the exon 2 to exon 7 region of the GS gene on chromosome 5 and design the targeting sgRNA sequence, the sequence of which is as follows: The sgRNA sequence targeting intron 1 is: 5'-CCCTGCAGGAATTGCGTAAG-3' (SEQ ID NO. 17); the sgRNA sequence targeting exon 7 is: 5'-GGTAGCCCTACTGTAAAAGA-3' (SEQ ID NO. 18).

[0090] (2) Based on a comprehensive analysis of the exon sequences of the GS gene on chromosome 1, we designed the targeting sgRNA sequence as follows: 5' end targeting sgRNA sequence: 5'-AATTAGGCCGAGCCGAGAAT-3' (SEQ ID NO. 19); 3' end targeting sgRNA sequence: 5'-CTTCATTGTAACTCAAAGGA-3' (SEQ ID NO.20).

[0091] (3) Synthesize sgRNA primers (Suzhou Jinweizhi), use sgRNA primer pairs to perform PCR reaction, and obtain a large number of sgRNA in vitro transcription templates. The template used in the PCR reaction is the pUC-sgRNA vector containing tracrRNA, and the system is: ddH2O 6μL, sgRNA F 0.5μL, sgRNA R 0.5μL, template 1μL, 2xTaq master mix (CW0682) 7.5μL. The program is: 95℃ 3 minutes, 95℃ 30 seconds, 64℃ 30 seconds, 72℃ 10 seconds, and 34 cycles.

[0092] The tracrRNA sequence is as follows (SEQ ID NO.21):

[0093] The forward primer sequence of the sgRNA targeting intron 1 is as follows (SEQ ID NO.22):

[0094] The forward primer sequence of the sgRNA targeting exon 7 is as follows (SEQ ID NO.23):

[0095] The forward primer sequence of the 5' end targeting sgRNA is as follows (SEQ ID NO.24):

[0096] The forward primer sequence for 3' end targeting sgRNA is as follows (SEQ ID NO.25):

[0097] (4) The PCR product obtained in step (3) was excised and recovered (DP209-02) to a concentration of 1 μg / μL.

[0098] (5) In vitro transcription of sgRNA (Invitrogen, AM1333), reaction system: ATP 2 μL, GTP 2 μL, CTP 2 μL, UTP 2 μL, 10x buffer 2 μL, T7 Polymerase 2 μL, sgRNA template (purified in step (3)) 1 μL, ddH2O 7 μL; reaction conditions: incubation at 37°C for 2-4 hours.

[0099] (6) Take 1 μL of the product from step 4 and perform electrophoresis on a 2% agarose gel for verification (see Figure 2 ), successfully obtaining high-quality sgRNA.

[0100] (7) Add 1 μL of DNaseI to the sgRNA in vitro transcription reaction system in step (5) and digest at 37°C for 15 minutes, then add EDTA to terminate the reaction, followed by chloroform extraction and ethanol precipitation to recover and purify the sgRNA.

[0101] (8) Discard the ethanol in step (7), place in a vacuum concentrator to dry, then add 80 μL of Nuclease-free water to dissolve the sgRNA, and store at -80°C for later use.

[0102] (9) Prepare the RNP complex on the day of electroporation, and combine the Cas9 protein with the sgRNA at room temperature to obtain the RNP complex.

[0103] (10) Prepare CHO-K1 (ATCC: CCL-61) suspension cells in advance, resuscitate and stabilize for 3 generations, and then take cells in the logarithmic growth phase on the day of electroporation for electroporation using the Neon transfection system. The electroporation conditions are: cell density 2x10 7 cells / mL, 100μL system (Thermo fisher, MPK10025), 1600V / 20msec / 1pulse.

[0104] (11) The electroporated CHO-K1 cells were allowed to recover for 48 h in OPM-Altair medium (4 mM glutamine) and single colonies were plated using the mouth pipette selection method.

[0105] (12) When the confluence rate of the single clone reaches about 60%, remove some cells and centrifuge at 12000g for 2 minutes. Add 100 μL of 50 mM NaOH and heat in a metal bath at 95°C for 10 minutes. Remove and add 100 μL of TE, vortex and centrifuge at 12000g for 2 minutes.

[0106] (13) Take 1 μL of the supernatant in step (12) and perform PCR reaction to verify the knockout of GS. A total of 6 pairs of primers were designed for the knockout of GS. When naming the primers below, the GS gene on chromosome 5 is referred to as GS5, and the GS gene on chromosome 1 is referred to as GS1. The primer pair sequences are as follows:

[0107] (14) In step (13), the primer pair of GS5-WT5'F1 (SEQ ID NO.27) and GS5-WT3'R (SEQ ID NO.30) and GS1-WT5'F (SEQ ID NO.31) and GS1-WT3'R (SEQ ID NO.34) are primers for identifying knockout cells, and their PCR products contain sequences at both ends of the knockout fragment. In the knockout cell line, the product is short due to the lack of the knockout sequence and can be detected, while in the non-knockout cell line, the product is as long as about 7kb and cannot be amplified. See Figure 3 As shown in the figure, lane numbered 1 is cell line B, and lane numbered 20 is cell line A. The products of the above two primer pairs were excised and recovered, and Sanger sequencing was performed for verification.

[0108] Experimental results: Sanger sequencing results are shown in Figure 4 As shown, the sequence targeted by sgRNA on the GS gene on chromosome 5 was successfully knocked out, including its intron 2 to exon 7 (SEQ ID NO.35); the sequence of the GS gene on chromosome 1 including the entire exon (SEQ ID NO.36) was successfully knocked out, indicating that the GS knockout cell line was successfully obtained. Among them, the GS5 and GS1 double knockout cell line A (GS5- / -; GS1- / -) and the GS5 double knockout cell line B (GS5- / -) were screened.

[0109] SEQ ID NO.35: GS5 knockout sequence, total length 5385 bp, including intron 1 to exon 7 sequence

[0110] SEQ ID NO.36: GS1 knockout sequence, total length 1325 bp, including the entire exon sequence

[0111] Example 2: GS knockout validation (1) RT-PCR primers were designed for the GS gene to detect the absence of GS at the RNA level. The primer pair sequences are as follows:

[0112] (2) Take 1x10 6 The wild-type CHO-K1 cells, cell line A cells and cell line B cells were centrifuged at 12000g for 2 minutes and the supernatant was discarded.

[0113] (3) According to the operating manual of QIAGENE (74104) RNeasyminikit, add 350 μL of cell lysis buffer to each of the three groups of cells in step (2), grind with a small electric grinder for 15 seconds, and immediately add 350 μL of 70% anhydrous ethanol, and mix by gently pipetting up and down with a pipette.

[0114] (4) Add the supernatant from step (3) into a 2 mL centrifuge tube containing an adsorption column, centrifuge at 8000 g for 30 seconds, and discard the liquid.

[0115] (5) Add 700 μL of liquid RW1 to the adsorption column, centrifuge at 8000 g for 30 seconds, and discard the liquid.

[0116] (6) Add 500 μL of liquid RPE to the adsorption column, centrifuge at 8000 g for 30 seconds, and discard the liquid.

[0117] (7) Add 500 μL of liquid RPE to the adsorption column, centrifuge at 8000 g for 2 minutes, and discard the liquid.

[0118] (8) Discard the liquid and place the adsorption column back into a 2 mL centrifuge tube. Centrifuge at 12,000 g for 2 minutes.

[0119] (9) Remove the adsorption column and place it in a new 1.5 mL centrifuge tube. Add 40 μL of nuclease-free water and centrifuge at 12,000 g for 2 minutes. Use Nanodrop to measure RNA concentration.

[0120] (10) Take equal amounts of RNA (500-1 μg) from the three groups of cells obtained in step (9) and transcribe using the Bio-Rad iScript cDNA synthesis kit. The reaction system is: 4 μL of 5x iScript reaction solution, 1 μL of iScript reverse transcriptase, RNA (500-1 μg), and nuclease-free water to 20 μL. The reaction conditions are: 25°C for 5 minutes, 46°C for 20 minutes, 95°C for 1 minute, and storage at 4°C.

[0121] (11) Take 1 μL of the cDNA obtained in step (10) as a template, the primer pair in step (1) as primers, and set up a no-template negative control for PCR reaction.

[0122] Experimental results: DNA gel electrophoresis results show (see Figure 5 ), in the wild-type CHO-K1, all primer pairs could detect the product; in the A cell line, only the GS5-E1F and GS5-E2R primer pairs could detect the product, while the GS5-E2F and GS5-E3R primer pairs, the GS5-E6F and GS5-E7R primer pairs, and the GS1-F and GS1-R primer pairs could not detect the product; in the B cell line, the GS5-E1F and GS5-E2R primer pairs and the GS1-F and GS1-R primers could all detect the product.

[0123] Example 3: Verification of GS gene functional defect Wild-type CHO-K1 cell line, cell line A and cell line B were cultured in medium without glutamine, 1 mM glutamine, 2 mM glutamine, 4 mM glutamine and 8 mM glutamine, and cell viability and density were monitored daily. The initial inoculum cell density was 5x10 5 cells / mL, the volume is 10mL.

[0124] Experimental results (see Figure 6 ): In the culture medium without glutamine, the wild-type cell line, cell line A and cell line B could not survive normally, among which cell lines A and B died rapidly and massively within 2 days, and the wild-type cell line was almost completely dead after 4 days; in the culture medium with low concentration of glutamine (1mM and 2mM), the growth rate of cell line A and cell line B was slower than that of the wild-type cell line; in the culture medium with high concentration of glutamine, there was no difference in the growth rate and viability of the three groups of cell lines.

[0125] Example 4: Screening and application of GS cell-deficient subclone cell lines with high expression levels (1) Cell lines A and B were plated for monoclonal colonies by mouth pipette selection. 8 mM glutamine was added to the culture medium used for plating, and 100 μL of culture medium was added to each well.

[0126] (2) 37°C, 5% CO 2 The cells were cultured statically in an incubator and refilled with 35 μL of fluid every 3 days.

[0127] (3) The three subclones that first reach a cell confluence rate of more than 60% are selected and numbered A1, A2, A3, B1, B2 and B3. It usually takes 10 to 14 days for the confluence rate to reach 60%.

[0128] (4) The 6 subcloned cell lines in step (3) were expanded and subcultured from the 96-well plate to the 24-well plate. When the confluence rate reached about 80%, they were subcultured to T25 culture flasks. Finally, when the cell density reached 5x10 5 cells / mL, expand the culture to shake flasks and store them in cryopreserved form as required.

[0129] (5) The constructed recombinant protein expression vector carrying exogenous GS was transferred into A1, A2, A3, B1, B2 and B3 cell lines in the logarithmic growth phase. On the day of transfection, 300,000 cells were mixed with 1 μg of plasmid vector and electroporated using the Thermo Neon transfection system. The transfection conditions were 1400V / 10msec / 3pulses.

[0130] (6) The transfected cells were placed in a culture medium containing 4 mM glutamine and allowed to recover for 48 hours.

[0131] (7) After 48 hours, medium without glutamine was added for half-medium replacement screening culture. Cell viability and density were tested every other day, and the time required for cell viability recovery was recorded for each cell line.

[0132] (8) When the cell line viability reaches more than 90%, subculture it into a shake flask and culture it for more than three generations.

[0133] (9) The cell lines prepared in step (8) are plated for monoclonal proliferation. When the confluence rate of the monoclonal cell lines reaches more than 60%, ELISA is performed to select the three monoclonal cell lines with the best reactions, which are numbered A11, A12, A13, A21, A22, A23, A31, A32, A33, B11, B12, B13, B21, B22, B23, B31, B32 and B33.

[0134] (10) After the 18 cell lines in step (9) were expanded and cultured, 2×10 5 Cells / mL density was inoculated and cultured, and the cell density reached 1x10 6 When the cell count was 2.5447 cells / mL, feeding induction was started. The added feeding solution Cytiva 7a (5%) and Cytiva7b (0.5%) maintained the glucose content in the culture medium at 7 g / L. The cell density, viability and antibody expression were recorded every day.

[0135] (11) When the cell density stabilizes and the viability begins to drop to 80%, the feeding induction is stopped and the final expression level of the cell line is determined based on this.

[0136] Experimental results (see Figure 7 and Figure 8 ): Figure 7Shown in the figure is the screening recovery time required for 18 monoclonal cell lines, among which A12 (named Chinese hamster ovary cell CHO-K1 / LG-GSKa1 Chinese Hamster Ovary, deposited in China Center for Type Culture Collection on May 29, 2024; deposit number is CCTCCNO: C2024149) and B21 (named Chinese hamster ovary cell CHO-K1 / LG-GSKb2 Chinese Hamster Ovary, deposited in China Center for Type Culture Collection on May 29, 2024; deposit number is CCTCCNO: C2024167) have relatively short screening cycles; Figure 8 The expression levels of recombinant proteins of the 18 monoclonal cell lines are shown in the figure. They all obtained a relatively high recombinant protein expression level. Among them, the recombinant protein expression levels of the 9 subclone cells of the A cell line were relatively higher than that of the B cell line. The overall advantages of the three subclones of A1 were obvious over the other cell lines, and A12 was the best cell line.

[0137] The above results show that the A1 monoclonal GS-deficient subclone cell line discovered was obtained by combining multiple methods such as screening cycles and recombinant protein expression tests on the GS-deficient cell line. It has the characteristics of high protein expression, no need for MSX screening, short screening cycle, and safety and reliability in production applications.

[0138] The raw materials and equipment used in the present invention, unless otherwise specified, are all commonly used raw materials and equipment in the art; the methods used in the present invention, unless otherwise specified, are all conventional methods in the art.

[0139] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent transformation made to the above embodiment based on the technical essence of the present invention still falls within the protection scope of the technical solution of the present invention.

Claims

1. A method for preparing a CHO-K1 monoclonal cell line with GS biallelic knockout, characterized in that include: 1) Analyze the GS gene on chromosomes 5 and 1 of CHO-K1 cells, develop a knockout plan, and design the Cas9-guided sgRNA sequence that recognizes the GS gene; 2) Connect the tracrRNA sequence to the 20nt sgRNA sequence and synthesize the PCR reaction primer; 3) PCR amplification to obtain the sgRNA in vitro transcription template; 4) Obtaining sgRNA containing sgRNA sequence and tracrRNA sequence by in vitro transcription with RNA polymerase; 5) Combine sgRNA with Cas9 protein to form RNP complex, and transfect into CHO-K1 cells; 6) Monoclonal culture to obtain CHO-K1 monoclonal cell line with GS double allele knockout.

2. The preparation method according to claim 1, characterized in that: 1) In Two sgRNAs were designed for each GS gene on each chromosome; For chromosome 5, there are sgRNA sequences targeting intron 1 and sgRNA sequences targeting exon 7; Targeting chromosome 1 are 5' end targeting sgRNA sequence and 3' end targeting sgRNA sequence.

3. The preparation method according to claim 2, characterized in that: 1) In The sgRNA sequence targeting intron 1 is shown in SEQ ID NO.17; the sgRNA sequence targeting exon 7 is shown in SEQ ID NO.18; The 5' end targeting sgRNA sequence is shown as SEQ ID NO.19; the 3' end targeting sgRNA sequence is shown as SEQ ID NO.

20.

4. The preparation method according to any one of claims 1 to 3, characterized in that: 2), the tracrRNA sequence is shown in SEQ ID NO.

21.

5. The preparation method according to claim 4, characterized in that: 2), the PCR reaction primers include: For chromosome 5: the forward primer sequence of the sgRNA targeting intron 1 is shown in SEQ ID NO.22; the forward primer sequence of the sgRNA targeting exon 7 is shown in SEQ ID NO.23; For chromosome 1: the forward primer sequence of the 5' end targeting sgRNA is shown in SEQ ID NO.24; the forward primer sequence of the 3' end targeting sgRNA is shown in SEQ ID NO.

25.

6. The preparation method according to claim 1, characterized in that: 5) In The transfection method is electrotransfection or liposome transfection; The source of the CHO-K1 cells is ATCC: CCL-61.

7. The preparation method according to claim 1, characterized in that: 6), the monoclonal culture method is: statically culture the transfected CHO-K1 cells, pick cells with a relatively round shape and medium size, place one cell in each well, perform monoclonal plating, and check at two time points after 2 hours and within 24 hours to determine the monoclonal cell wells and exclude non-monoclonal cell wells.

8. The preparation method according to claim 1 or 7, characterized in that: 6) When the confluence rate of monoclonal cells reaches 55-65%, DNA extraction, PCR detection and Sanger sequencing verification are performed to obtain a CHO-K1 monoclonal cell line with GS biallelic knockout.

9. The preparation method according to claim 1, characterized in that: Also includes: 7) Expand the culture and cryopreservation of CHO-K1 monoclonal cell lines with GS biallelic knockout; 8) The GS biallelic knockout CHO-K1 monoclonal cell line obtained in 7) was verified for GS RNA level, protein level and functional defect, and a high-expressing GS biallelic knockout CHO-K1 monoclonal cell line was obtained after screening.

10. The preparation method according to claim 9, characterized in that: 8) Specifically include: A) The GS biallelic knockout CHO-K1 monoclonal cell line was subcloned and plated by mouth pipette selection; B) Expand the culture of the subclone cells that first grow to 70-80% confluence and have uniform cell size and freeze them for seed preservation; C) Transfect the constructed recombinant protein expression vector into the subclone cell line obtained in B); D) The transfected subcloned cell lines were placed in medium containing glutamine to recover; E) The recovered subcloned cell lines were placed in a medium without glutamine for screening; F) Continuously monitor the density and viability of subcloned cell lines; G) When the cell viability reaches more than 90%, the growth rate is normal and can be stable for 3 generations, monoclonal plating is performed by mouth pipette selection method; H) When the growth confluence rate of the monoclonal cell lines in G) reaches 45-55%, ELISA reaction screening is performed to select the monoclonal cell lines with high expression levels; I) expanding the culture of the monoclonal clone obtained in H) and performing Fed-Batch induced expression; J) Monitor the expression level of the cell lines in I), analyze the time required for each monoclonal cell line to go from E) to G), and analyze the expression level of the recombinant protein to select the optimal subclone cell line.